ABSTRACT
Objective To explore the effect and adverse reaction of different neoadjuvant chemotherapy regimens:docetaxel + THP + cyclophosphamide and docetaxel + THP in the treatment of triple negative breast cancer.Methods The clinical data of 75 patients with triple negative breast cancer in type Ⅱa-Ⅲc period were retrospectively analyzed.According to different treatment method,they were divided into two groups.The observation group (43 cases)was given the treatment of TAC,the control group (32 cases) was given the treatment of AT.The short-term efficacy and adverse reaction were evaluated and analyzed before every course of treatment,the total effective rate was evaluated after four courses of treatment.The long-term curative effect of the two groups was evaluated by following-up.Results The total effective rate of the observation group was 90.70％,which was significantly higher than 71.88％ of the control group (x2 =4.536,P =0.033).The incidence rates of adverse effects of chemotherapy in the observation group were higher than the control group,but there were no statistically significant differences between the two groups (gastrointestinal disorder x2 =2.931,P =0.087;marrow depression x2 =1.586,P =0.208;baldness x2 =1.367,P =0.242;cardiotoxicx2 =1.114,P =0.291).The three years survival rates in the observation group and the control group were 93.02％ and 87.50％ respectively,there was no statistically significant difference between the two groups(x2 =0.940,P =0.332).Conclusion The neoadjuvant chemotherapy of TAC and AT is both effective in the treatment of triple negative breast cancer,and TAC scheme is superior to AT scheme,the long-term efficacy in the two schemes has no significant difference.
ABSTRACT
Objective To study the clinical pathological characteristics and prognostic factors of carcinosarcoma in corpora uteri.Methods Clinical data of 17 corpora uteri carcinosarcoma patitents diagnosed in Jining Medical University from June 2008 to December 2013 were analyzed.Results In 17 cases of uterine sarcoma,I had 3 cases, 4 cases of stageⅡ,8 cases of stage Ⅲ,and 1 case of stage Ⅳ.The overall survival rates of the 3 years and stage Ⅲ ~Ⅳ were 62.5% and 11.1%,respectively.The 3 -year survival rate was 100.0%,and the 5 -year survival rates of stageⅠ ~Ⅱ,Ⅲ ~Ⅳ were 37.5%,0.0%,respectively.Univariate analysis showed that the staging influenced the prognosis.Conclusion The prognosis of patients with uterine sarcoma is related to the surgical pathologic stage.
ABSTRACT
Background and purpose:Multidrug resistance(MDR)is the main obstacle of chemotherapy in the treatment of cancer,and it has been reported that the muted p53 gene is related to MDR.In this study,we explored whether adenovirus mediated p53 gene(Ad-p53)could reverse MDR of human breast cancer and its impacts on the expressions of P-gp,TOPOⅡ and GST-?.Methods:In this study,adriamycin-resistant human breast carcinoma cells(MCF-7/Adr)and its parental cells(MCF-7)were used to determine the effect of Ad-p53.Cck-8 assay was adopted to evaluate the cytotoxicity of adriamycin.Western blot were performed to observe the expression of P-glycoprotein(P-gp),TopoismeraseⅡ(TOPOⅡ)and GST-?.Results:After transfection with 50 MOI Ad-p53,the 50% inhibitory concentration(IC50)of adriamycin to MCF-7/Adr cells was decreased from(4.54?0.91)?g/ml to(0.26?0.11)?g/ml,and the chemosensitivity increased 18.1 times(P
ABSTRACT
Background and purpose:There is a tendency to treat tumors through multiple genes and multiple targeting but there has been no reports about the therapeutic effect of recombinant human endostatin(ES)combined with rAd/p53 on graft model of human breast cancer.Methods:MCF-7 human breast cancer cells were inoculated in nude mice.Then the nude mice with xenograft tumor were randomized into groups of control,ES,rAd/p53,and ES + rAd/p53,they were treated according to the plan.Diversity of the xenograft tumor volume and side effect was observed.Microvessel density(MVD)and expression of vascular endothelial growth factor(VEGF)were detected by immunohistochemistry.Results:After the administration of ES,rAd/p53,ES + rAd/p53,the growth of tumor was inhibited with the inhibitory rate of 1.75%,43.36% and 58.68%,respectively.Inhibition of tumor growth was significant in Group rAd/p53 and ES + rAd/p53(P0.05).Conclusions:recombinant human endostatin combined with rAd/p53 can greatly inhibit growth of xenograft tumor,and reduce the generation of capillary vessels.
ABSTRACT
Objective:To investigate the inhibitory effect of recombinant human endostatin(ES)combined with rAd/P53 on transplanted human breast cancer cell MCF-7 in nude mice.Methods:Animal breast cancer model was established by inoculating MCF-7 cells in nude mice.The animals were randomized into control group,ES group,rAd/P53 group,and ES+ rAd/P53 group.The tumor growth was observed in each group and immunohistochemical method was employed to examine the microvessel density(MVD) and the expression of vascular endothelial growth factor(VEGF).Results:Tumor growth was significantly inhibited in all the 3 treatment groups(P
